Our ultimate vision is to prevent and provide cures for cancer in all its forms. Recognizing that no single intervention can achieve this comprehensive goal, we strive to deeply understand the disease, its complexities, and its impact on patients.
We are proud to have the broadest and most diverse pipeline in oncology, with more than 20 immunotherapy molecules currently in development. Since 2011, we have introduced 18 oncology medicines. Our efforts are united by a commitment to exploring therapeutic combinations and pursuing personalized medicines.
Reflecting our pharma strategy, we aim to bolster end-to-end investment in key disease areas (lung cancer, breast cancer, and malignant hematological conditions), while continually seeking transformative medicines in other areas. This integrated approach ensures that we address the full spectrum of patient needs, from prevention and diagnosis to treatment and beyond.
With a special interest in lung, breast, and heme we remain interested in other areas or biologies
Adaptive and innate immunity
Antibody Drug Conjugates (ADCs)
Off-The-Shelf Cell therapies
Cancer cell dependenciesDNA Damage Response/ Synthetic lethality
Neoantigens
Oncogenic drivers
Stromal biology
If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.